New drug cocktail and High-Tech scans aim to improve prostate cancer care
NCT ID NCT03860987
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 32 times
Summary
This study tested a combination of three hormone-blocking drugs (abiraterone, enzalutamide, and standard hormone therapy) given before surgery to men with newly diagnosed prostate cancer that hadn't spread. The goal was to see if this approach could shrink tumors and improve detection using advanced MRI and PET/CT scans with a new radioactive tracer. Twelve men participated, and the study tracked how well the treatment worked and how the scans could better find cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATE SENSITIVE PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.